HUNTSVILLE, AL., Oct. 08, 2025 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary POZ Platform ™ drug optimization technology, today announced the launch of a comprehensive corporate communications platform designed to deliver timely, transparent updates to patients, clinicians, investors, and the broader scientific community. The... Read More

$5 million tranche received under up to $20 million financing agreement IND submitted to FDA and HREC approval obtained in Australia; global trial initiation in Q4 2025 HUNTSVILLE, AL, Oct. 06, 2025 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary POZ Platform ™ drug optimization technology, today announced the drawdown of the... Read More

Transaction structured to provide flexible funding to support Phase 1b registrational clinical study program in advanced Parkinson’s under the 505(b)(2) NDA pathway Evaluating complementary funding including strategic equity and non-dilutive alternatives HUNTSVILLE, AL, Sept. 09, 2025 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company developing its... Read More

HUNTSVILLE, AL, Sept. 08, 2025 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary POZ Platform ™ drug optimization technology, announced that Steve Ledger, Chief Executive Officer, will present at the H.C. Wainwright 27 th Annual Global Investment Conference in New York, NY on September 8, 2025, at 9:30 a.m. ET. A live webcast of... Read More

U.S. IND filing planned for Q4 2025 with U.S. enrollment expected to start in Q1 2026 Patient dosing expected to begin in Australia in Q4 2025 HUNTSVILLE, AL, Aug. 25, 2025 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc . (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary POZ Platform ™ drug optimization technology, today announced that following a recent Type B meeting with the... Read More

HUNTSVILLE, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company advancing its lead IND candidate, SER-252, for advanced Parkinson's disease, enabled by its proprietary POZ Platform ™ drug optimization technology, today announced its financial results for the second quarter ended June 30, 2025, along with key recent updates. “We’re proud of the... Read More

Novel once-weekly injectable VMAT2 inhibitor targets underserved patients with serious adherence and access challenges Potential expansion into Huntington’s chorea – an underserved indication with high need for long-acting VMAT2 therapy HUNTSVILLE, AL, July 29, 2025 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary POZ Platform ™... Read More

HUNTSVILLE, AL, July 28, 2025 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary POZ Platform ™ drug optimization technology, today announced that Steve Ledger, Chief Executive Officer, will participate in a fireside chat at the BTIG Virtual Biotechnology Conference, taking place July 29-30, 2025. The discussion will be held on... Read More

HUNTSVILLE, AL, July 10, 2025 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company advancing its lead IND candidate SER-252 for advanced Parkinson's disease, enabled by its proprietary POZ Platform ™ drug optimization technology, announced that it has made a grant of options to purchase an aggregate of 12,500 shares of Serina’s common stock to a new... Read More

HUNTSVILLE, July 01, 2025 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company, today announced that its Board of Directors has established November 7, 2025, as the date of its 2025 annual meeting of stockholders (the “Annual Meeting”). The time and location of the Annual Meeting will be set forth in the Serina’s definitive proxy statement for the Annual... Read More

How Parkinson’s affects million – and why current treatments are not enough Continuous dopaminergic stimulation (CDS): a next-gen approach to Parkinson’s care Serina’s drug candidate SER-252 is designed to deliver continuous symptom relief Join Serina CEO Steve Ledger for this live event hosted by FORCE Family Office HUNTSVILLE, AL, June 23, 2025 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina”) (NYSE American: SER),... Read More

HUNTSVILLE, June 17, 2025 (GLOBE NEWSWIRE) -- This press release has been updated to reflect the correct timing of the funding round. Serina Therapeutics, Inc. (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary POZ Platform ™ drug optimization technology, today congratulates its strategic partner and largest shareholder, Juvenescence Ltd., on the $76 million first tranche close... Read More

HUNTSVILLE, June 17, 2025 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary POZ Platform ™ drug optimization technology, today congratulates its strategic partner and largest shareholder, Juvenescence Ltd., on securing $150 million in Series B financing led by M42, a global tech-enables health company headquartered in Abu Dhabi.... Read More

Featuring Serina Therapeutics’ CEO - Wednesday, June 11, 2025 Entering year 5 of a biotech bear market, approximately 25% of the 700 – 800 publicly traded US biotech companies have negative enterprise values Recognize the patterns that can lead to strong investment returns Meet with Serina’s CEO Steven A. Ledger Register at Smartest-Bet.TribePublic.com HUNTSVILLE, AL, June 09, 2025 (GLOBE NEWSWIRE) -- Serina Therapeutics,... Read More

Renowned neuroscience drug developer joins to support strategic development of long-acting CNS therapeutics HUNTSVILLE, AL, May 22, 2025 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company developing a pipeline of product candidates leveraging its proprietary POZ Platform ™ drug optimization technology, today announced the appointment of Stephen (Steve)... Read More

HUNTSVILLE, AL, May 14, 2025 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company advancing its lead IND candidate SER-252 for advanced Parkinson's disease, enabled by its proprietary POZ Platform ™ drug optimization technology, announced that it has made grants of options to purchase an aggregate of 15,000 shares of Serina’s common stock to two new... Read More

On track for first patient dosing of SER-252 in Phase 1b clinical trial in advanced Parkinson’s disease in Q4 2025 Strengthened balance sheet with recent financing Advancing innovative POZ Platform across multiple therapeutic modalities Two new seasoned biotech leaders added to the Board of Directors HUNTSVILLE, May 08, 2025 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina”) (NYSE American: SER), a clinical-stage... Read More

HUNTSVILLE, AL, April 29, 2025 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary POZ Platform ™ drug optimization technology, announced that Steve Ledger, Chief Executive Officer, will present at the JonesResearch Hosts: Virtual CNS Day on April 29, 2025, at 12:00 p.m. EDT. A live webcast of the fireside chat style presentation... Read More

HUNTSVILLE, AL, April 15, 2025 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary POZ Platform ™ drug optimization technology, announced that Randall Moreadith, M.D., Ph.D., Chief Development Officer, will present new data at the 4th LNP Formulation & Process Development Summit 2025 in Boston, MA. The presentation, titled "The PEG... Read More

HUNTSVILLE, Ala., April 08, 2025 (GLOBE NEWSWIRE) -- S erina Therapeutics, Inc. (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary POZ Platform ™ drug optimization technology, today announced the closing of a $5 million financing from strategic shareholders. Proceeds from the transaction will support the continued development of SER-252 (POZ-apomorphine), Serina's lead clinical... Read More

HUNTSVILLE, AL, April 07, 2025 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary POZ Platform ™ drug optimization technology, announced that Steve Ledger, Chief Executive Officer, will present at the Jones Healthcare and Technology Innovation Conference in Las Vegas, NV on April 9, 2025, at 3:00 p.m. PDT. A live webcast of the... Read More

HUNTSVILLE, March 24, 2025 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary POZ Platform ™ drug optimization technology, today reported its financial results for the full year ended December 31, 2024 and provided recent business highlights. "We are encouraged by the progress we’ve made this year. Our partnership with Enable... Read More

HUNTSVILLE, AL, March 24, 2025 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary POZ Platform ™ drug delivery technology, announced that Randall Moreadith, M.D., Ph.D., Chief Development Officer, will present new data at the ACS Spring 2025 Meeting and Expo in San Diego, CA. His presentation, titled "A Non-Immunogenic LNP for Gene... Read More

HUNTSVILLE, AL, Feb. 12, 2025 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary POZ Platform ™ drug optimization technology, today announced the appointment of Jay Venkatesan, MD, MBA, to its Board of Directors. Dr. Venkatesan brings deep expertise in biotechnology investment, company building, and strategic growth, having... Read More

HUNTSVILLE, Feb. 03, 2025 (GLOBE NEWSWIRE) -- S erina Therapeutics, Inc. (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company, today announced the successful closing of the second $5 million tranche of its previously announced $10 million equity financing with strategic shareholder JuvVentures (UK) Limited. The transaction provides Serina with funding to continue advancing SER-252 (POZ-apomorphine),... Read More

Transaction eliminates $11.2 million in debt, strengthening financial position HUNTSVILLE, AL, Jan. 15, 2025 (GLOBE NEWSWIRE) -- Serina Therapeutics Inc. (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary POZ Platform ™ drug delivery technology, today announced the sale of its UniverXome subsidiary. The transaction was finalized on December 23, 2024 and eliminated $11.2 million... Read More

HUNTSVILLE, AL, Jan. 14, 2025 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary POZ Platform ™ drug delivery technology, today announced the appointment of Karen J. Wilson to the Board of Directors. "We are excited to welcome Karen to the Board of Directors. Karen’s financial expertise and deep understanding of the biotech... Read More

Meet with Serina’s CEO Steven A. Ledger Parkinson's disease is a progressive neurological disorder that primarily affects movement Continuous dopaminergic stimulation (CDS) has been shown to reduce the severity of motor complications (dyskinesia) in advanced Parkinson’s patients Discussion of the Serina IND candidate’s target product profile versus the current standard of care in providing CDS HUNTSVILLE, AL, Dec. 16, 2024... Read More

HUNTSVILLE, AL, Dec. 11, 2024 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary POZ Platform ™ drug delivery technology, announced that Serina Therapeutics' Chief Development Officer, Randall Moreadith, MD, PhD, will be presenting today at the 3rd Annual LNP Immunogenicity & Toxicity Summit in Boston, MA. Entitled "Overcoming... Read More

HUNTSVILLE, Dec. 02, 2024 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company, today announced a $10 million equity financing with strategic shareholder JuvVentures (UK) Limited. The transaction provides Serina with funding to continue advancing SER-252 (POZ-apomorphine), enabled by its proprietary POZ Platform ™ drug optimization technology, into a Phase 1... Read More

HUNTSVILLE, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company advancing its lead IND candidate SER-252 for advanced Parkinson's disease, enabled by its proprietary POZ Platform ™ drug optimization technology, today announced its financial results for the third quarter ended September 30, 2024, along with key recent updates. Recent Highlights... Read More

HUNTSVILLE, AL, Nov. 11, 2024 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company advancing its lead IND candidate SER-252 for advanced Parkinson's disease, enabled by its proprietary POZ Platform ™ drug optimization technology, announced that it has made grants of options to purchase an aggregate of 60,500 shares of Serina’s common stock to three new... Read More

HUNTSVILLE, AL, Oct. 02, 2024 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary POZ Platform ™ drug delivery technology, announced that Serina Therapeutics' Chief Development Officer, Randall Moreadith, MD, PhD, will be presenting today at the 14th Annual Injectables Summit in Boston, MA. The joint presentation, with Enable... Read More

HUNTSVILLE, Sept. 04, 2024 (GLOBE NEWSWIRE) -- Serina Therapeutics (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary POZ Platform ™ drug delivery technology, today announced that Steve Ledger, Interim Chief Executive Officer of Serina, will present at the H.C. Wainwright 26th Annual Global Investment Conference on September 11, 2024, at 12:00 p.m. ET. A live webcast of the... Read More

HUNTSVILLE, Aug. 09, 2024 (GLOBE NEWSWIRE) -- Serina Therapeutics (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary POZ Platform ™ drug delivery technology, today reported financial results for the quarter ended June 30, 2024 and provided business highlights. Recent Highlights ● Partnership with Enable Injections. The Company will develop and commercialize SER-252... Read More

HUNTSVILLE, July 29, 2024 (GLOBE NEWSWIRE) -- Serina Therapeutics (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary POZ Platform TM drug delivery technology, today announced that Randall Moreadith, MD, Ph.D., Chief Development Officer, will present at the 4th Annual mRNA-Based Therapeutics Summit. The conference will take place from July 29-31, 2024, in Boston, MA. Dr.... Read More

ALAMEDA, Calif., March 22, 2024 (GLOBE NEWSWIRE) -- AgeX Therapeutics, Inc. (“AgeX”; NYSE American: AGE), a biotechnology company developing therapeutics for human aging and regeneration, reported its financial and operating results for fourth quarter and the full year ended December 31, 2023 and recent highlights. Recent Highlights ● Stockholders approved transactions for merger with Serina Therapeutics, Inc. ● Obtained... Read More

ALAMEDA, Calif. / Nov 14, 2023 / Business Wire / AgeX Therapeutics, Inc. (“AgeX”; NYSE American: AGE), a biotechnology company developing therapeutics for human aging and regeneration, reported its financial and operating results for the quarter and nine months ended September 30, 2023. Third Quarter and Recent Highlights $36 Million of Indebtedness Converted into Preferred Stock Signed Agreement and Plan of Merger and... Read More

Merger to result in NYSE American-listed company focused on developing therapeutics based on Serina’s proprietary POZ Platform™ delivery technology Lead program of the combined company will be SER-252 (POZ-apomorphine) for the treatment of advanced Parkinson’s Disease Focus on expanding POZ Platform™ partnering collaborations across immunology, cancer Rx, and gene therapy fields HUNTSVILLE, Ala. & ALAMEDA, Calif. / Aug 30,... Read More

ALAMEDA, Calif. / Aug 14, 2023 / Business Wire / AgeX Therapeutics, Inc. (“AgeX”; NYSE American: AGE), a biotechnology company developing therapeutics for human aging and regeneration, reported its financial and operating results for the quarter and six months ended June 30, 2023. Balance Sheet Information Cash, cash equivalents, and restricted cash totaled $0.3 million as of June 30, 2023. Debt Exchanged for Preferred Stock... Read More

ALAMEDA, Calif. / Jul 24, 2023 / Business Wire / AgeX Therapeutics, Inc. (“AgeX”; NYSE American: AGE), a biotechnology company developing therapeutics for human aging and regeneration, reported that on July 24, 2023, AgeX issued to Juvenescence Limited 211,600 shares of a newly authorized Series A Preferred Stock and 148,400 shares of a newly authorized Series B Preferred Stock in exchange for the cancellation of a total of... Read More

ALAMEDA, Calif. / Jul 21, 2023 / Business Wire / AgeX Therapeutics, Inc. (“AgeX”; NYSE American: AGE), a biotechnology company developing therapeutics for human aging and regeneration, reported that on July 21, 2023, AgeX and Juvenescence Limited entered into an Exchange Agreement pursuant to which AgeX agreed to issue to Juvenescence 211,600 shares of a newly authorized Series A Preferred Stock and 148,400 shares of a newly... Read More

ALAMEDA, Calif. / May 23, 2023 / Business Wire / AgeX Therapeutics , Inc. (“AgeX”; NYSE American: AGE), a biotechnology company developing therapeutics for human aging and regeneration, announced today that on May 17, 2023 it received a notice from the staff of the NYSE American (the “Exchange”) indicating that they intend to commence proceedings to delist AgeX common stock from the Exchange based upon AgeX’s non-compliance... Read More

ALAMEDA, Calif. / May 12, 2023 / Business Wire / AgeX Therapeutics, Inc. (“AgeX”; NYSE American: AGE), a biotechnology company developing therapeutics for human aging and regeneration, reported its financial and operating results for quarter ended March 31, 2023. Balance Sheet Information Cash, cash equivalents, and restricted cash totaled $0.3 million as of March 31, 2023. As of March 31, 2023, AgeX owed Juvenescence... Read More

ALAMEDA, Calif. / Apr 26, 2023 / Business Wire / AgeX Therapeutics , Inc. (“AgeX”; NYSE American: AGE), a biotechnology company developing therapeutics for human aging and regeneration, announced today that on April 20, 2023 it received a letter (the “Deficiency Letter”) from the staff of the NYSE American (the “Exchange”) indicating that AgeX does not meet certain of the Exchange’s continued listing standards as set forth... Read More

ALAMEDA, Calif. / Mar 31, 2023 / Business Wire / AgeX Therapeutics, Inc. (“AgeX”; NYSE American: AGE), a biotechnology company developing therapeutics for human aging and regeneration, reported its financial and operating results for fourth quarter and the full year ended December 31, 2022. Balance Sheet Information Cash, cash equivalents, and restricted cash totaled $0.7 million as of December 31, 2022. As of December 31,... Read More